PT  - JOURNAL ARTICLE
AU  - Vincent Johan Nijenhuis
AU  - Jorn Brouwer
AU  - Lars Søndergaard
AU  - Jean-Philippe Collet
AU  - Erik Lerkevang Grove
AU  - Jurrien Maria Ten Berg
TI  - Antithrombotic therapy in patients undergoing transcatheter aortic valve implantation
AID  - 10.1136/heartjnl-2018-314313
DP  - 2019 May 01
TA  - Heart
PG  - 742--748
VI  - 105
IP  - 10
4099  - http://heart.bmj.com/content/105/10/742.short
4100  - http://heart.bmj.com/content/105/10/742.full
SO  - Heart2019 May 01; 105
AB  - This review provides a comprehensive overview of the available data on antithrombotic therapy after transcatheter aortic valve implantation (TAVI). In the absence of large randomised clinical trials, clinical practice is leaning towards evidence reported in other populations. Due to the greater risk of major bleeding associated with oral anticoagulation using a vitamin-K antagonist (VKA), antiplatelet therapy (APT) may be considered as the first-line treatment of patients undergoing TAVI. Overall, single rather than dual APT is preferred. However, dual APT should be considered in patients with a recent acute coronary syndrome (ie, within 6 months), complex coronary stenting, large aortic arch atheromas or previous non-cardioembolic stroke. Monotherapy with VKA should be considered if concomitant atrial fibrillation or any other indication for long-term oral anticoagulation is present. APT on top of VKA seems only reasonable in patients with recent acute coronary syndrome, extensive or recent coronary stenting or large aortic arch atheromas. A direct-acting oral anticoagulant may be considered if oral anticoagulation is indicated in the absence of contraindications. Initiation of VKA is indicated in clinical valve thrombosis, for example, with high transvalvular gradient, whereas the role of VKA in the case of subclinical leaflet thrombosis is currently uncertain.